#biopharmaceuticals #Denmark #Lundbeck #Valby #Vyepti

H. Lundbeck A/S Increases Revenue Guidance for 2026

H. Lundbeck A/S, a renowned biopharmaceutical company dedicated to brain health, has announced an update to its financial guidance for the fiscal year 2026. The company projects significant growth in both revenue and adjusted EBITDA at constant exchange rates (CER), largely propelled by exceptional performance in its flagship product, Vyepti®, in the U.S. market, along with stronger-than-expected results from partner markets.

Revised Financial Outlook

On November 10, 2026, Lundbeck revealed its revised guidance, which demonstrates a strong upward trajectory. The newly established revenue growth forecast is set between 11% to 12%, an increase from the previously anticipated range of 7% to 9%. Similarly, the adjusted EBITDA growth forecast has been upgraded to between 15% to 19%, surpassing the earlier estimate of 8% to 14%. This optimistic adjustment reflects Lundbeck's commitment to a robust growth strategy, fueled by its innovative product pipeline and solid market performance.

The company's revised expectations are primarily driven by improved revenue forecasts, indicating a critical affirmation of Lundbeck's market position and operational efficiency in delivering treatments for neurological and psychiatric conditions. Lundbeck plans to boost its research and development investments, forecasting expenditures in the range of DKK 5.6 to 5.7 billion.

Product Success and Market Strategy

A major highlight of Lundbeck’s financial uplift relates to Vyepti®, a treatment for migraine that has gained substantial traction in the U.S. Lundbeck's strategic initiatives and adaptive marketing efforts have enabled it to capture a larger share of the market. The positive consumer response underscores the efficacy of Vyepti® alongside other pivotal products in the company’s portfolio. As Lundbeck continues to innovate, the company remains dedicated to addressing numerous challenging brain disorders, ensuring a strong value proposition for its stakeholders.

Long-Term Commitment to Brain Health

For over 70 years, Lundbeck has focused exclusively on neurological and psychiatric health, allowing it to build a profound understanding of the complexities surrounding brain disorders. The company has a steadfast mission to enhance the lives of individuals suffering from such conditions. Lundbeck acknowledges the broader societal implications of brain health issues and actively works towards promoting health equity while fighting stigma associated with these disorders.

Furthermore, Lundbeck is committed to expanding its product offerings into neuro-specialty and neuro-rare markets, leveraging its legacy within psychiatry and neurology. It aspires to develop transformative medicines that are essential for patients with few or no treatment options.

Looking Ahead

The updated forecasts will be further discussed in the upcoming financial report covering the period from January 1 to September 30, 2026. Lundbeck’s transparency in financial guidance reflects its dedication to maintaining a trustworthy relationship with shareholders and fostering an environment of informed investment decisions.

Despite the optimistic outlook, Lundbeck reminds stakeholders of inherent risks outlined in the forward-looking statements, which encapsulate variations in market conditions, competition, and development hurdles that could influence operational results.

Overall, Lundbeck’s proactive approach and committed investment in brain health research underscore its goal to channel significant resources towards affecting positive change across affected populations and making substantial contributions to society at large.

For more information on Lundbeck's initiatives, products, and commitment to enhancing brain health, visit their official website at www.lundbeck.com.